Showing 4671-4680 of 8671 results for "".
- Galderma Completes Alastin Acquisitionhttps://practicaldermatology.com/news/galderma-completes-alastin-acquisition/2461026/Having received antitrust clearance from US authorities, Galderma has completed the acquisition of Alastin Skincare®, Inc., a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispens
- Survey: Consumers Interested in Medical Cannabis Products for Inflammatory Skin Disordershttps://practicaldermatology.com/news/survey-consumers-interested-in-medical-cannabis-products-for-inflammatory-skin-disorders/2461025/Patients with dermatologic conditions are open to trying medical cannabis products (MCPs) as potential treatments, according to a new study from George Washington University (GW) School of Medicine and Health Sciences (SMHS) and University of Maryland researchers. “MCPs, which are
- Dermatologist Tackles Misinformation Related to COVID-19 Vaccines and Injectable Fillers and Toxinxhttps://practicaldermatology.com/news/dermatologist-tackles-misinformation-related-to-covid-19-vaccines-and-injectable-fillers/2461022/With a recent article in the Wall Street Journal article suggesting that patients must choose between neurotoxin treatments or COVID-19 vaccines, dermatologists are scurrying to set the record straight. While there have been rare reports of non-life-threatening, transient reactions
- Case Study Highlights Possible Role for Minimal Dose Radiotherapy in Severe Acne Keloidalis Nuchaehttps://practicaldermatology.com/news/case-study-highlights-possible-role-for-minimal-dose-radiotherapy-in-severe-acne-keloidalis-nuchae/2461021/Minimal dose radiotherapy may offer new hope for severe acne keloidalis nuchae (AKN), according to research in the Journal of the American Academy of Dermatology Case Reports. The study found t
- Lilly's Lebrikizumab Plus Topical Corticosteroids Offer Improvement and Itch Relief in Atopic Dermatitishttps://practicaldermatology.com/news/lillys-lebrikizumab-plus-topical-corticosteroids-offer-improvement-and-itch-relief-in-atopic-dermatitis/2461015/Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's third pivotal Phase 3 trial (ADhere). By Week 16, the study met all primary and k
- Allergan Aesthetics Completes Acquisition of Solitonhttps://practicaldermatology.com/news/allergan-aesthetics-completes-acquisition-of-soliton/2461013/It’s official: Allergan Aesthetics, an AbbVie company, completed its acquisition of Soliton, Inc. The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body contouring treatments to now include the RESONIC device.
- NKTR-358 Demonstrates Proof of Concept in ADhttps://practicaldermatology.com/news/nktr-358-demonstrates-proof-of-concept-in-ad/2461011/Nektar Therapeutics and its partner Eli Lilly & Company’s NKTR-358 (LY3471851), a novel T regulatory (Treg) cell stimulator, demonstrated proof of concept in a Phase 1b study of patients with moderate-to-severe atopic dermatitis. The findings were presented at Eli Lilly&n
- NPF Launches Multimedia Resource Center for Health Care Providers Caring for Individuals with Psoriatic Diseasehttps://practicaldermatology.com/news/npf-launches-multimedia-resource-center-for-health-care-providers-caring-for-individuals-with-psoriatic-disease/2461008/The National Psoriasis Foundation (NPF) is committed to offering innovative ways for health care providers (HCPs) to stay up-to-date on the latest news and research related to psoriatic disease. As part of its five-year strategic plan to improve health outcomes for all living with the disease, in
- Top Researcher of Itch and Inflammatory Skin Conditions to Join Mount Sinai’s Department of Dermatologyhttps://practicaldermatology.com/news/top-researcher-of-itch-and-inflammatory-skin-conditions-to-join-mount-sinais-department-of-dermatology/2461006/One of the top researchers worldwide studying itch and inflammatory skin conditions, Brian S. Kim, MD, MTR, FAAD, will join Mount Sinai Health System as Director of the newly established Mark Lebwohl Center for Neuroinflammation and Sensation. Dr. Kim will also be Vice Chair of Research of the Ki
- JAK Inhibitor Combo Shows Promise in Alopecia Areatahttps://practicaldermatology.com/news/jak-inhibitor-combo-shows-promise-in-alopecia-areata/2461002/Ritlecitinib and brepocitinib show significant improvement in scalp alopecia areata biomarkers, according to a phase 2a clinical trial published inthe Journal of Allergy and Clinical Immunology. Rese